Venetoclax
Newly Diagnosed
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
30 Active assets in the Newly Diagnosed cohort.
View all 34 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →